Department of Medicine, Division of Endocrinology and Metabolism, UConn Health School of Medicine, Farmington, CT, 06030, USA.
Endocrinology. 2023 Nov 2;164(12). doi: 10.1210/endocr/bqad173.
We assessed the involvement of fibroblast growth factor 23 (FGF23) in phosphaturia in sickle cell disease (SCD) mice. Control and SCD mice were treated with FGF23 neutralizing antibody (FGF23Ab) for 24 hours. Serum ferritin was significantly increased in SCD mice and was significantly reduced in female but not male SCD mice by FGF23Ab. FGF23Ab significantly reduced increased erythropoietin in SCD kidneys. Serum intact FGF23 was significantly increased in SCD female mice and was markedly increased in SCD male mice; however, FGF23Ab significantly reduced serum intact FGF23 in both genotypes and sexes. Serum carboxy-terminal-fragment FGF23 (cFGF23) was significantly reduced in SCD IgG male mice and was markedly but not significantly reduced in SCD IgG female mice. FGF23Ab significantly increased cFGF23 in both sexes and genotypes. Serum 1,25-dihydroxyvitamin D3 was significantly increased in SCD IgG and was further significantly increased by FGF23Ab in both sexes and genotypes. Significantly increased blood urea nitrogen in SCD was not reduced by FGF23Ab. The urine phosphate (Pi)/creatinine ratio was significantly increased in SCD in both sexes and was significantly reduced by FGF23Ab. Increased SCD kidney damage marker kidney injury molecule 1 was rescued, but sclerotic glomeruli, increased macrophages, and lymphocytes were not rescued by short-term FGF23Ab. FGF23Ab significantly reduced increased phospho-fibroblast growth factor receptor 1, αKlotho, phosphorylated extracellular signal-regulated kinase, phosphorylated serum/glucocorticoid-regulated kinase 1, phosphorylated sodium-hydrogen exchanger regulatory factor-1, phosphorylated janus kinase 3, and phosphorylated transducer and activator of transcription-3 in SCD kidneys. The type II sodium Pi cotransporter (NPT2a) and sodium-dependent Pi transporter PiT-2 proteins were significantly reduced in SCD kidneys and were increased by FGF23Ab. We conclude that increased FGF23/FGF receptor 1/αKlotho signaling promotes Pi wasting in SCD by downregulating NPT2a and PIT2 via modulation of multiple signaling pathways that could be rescued by FGF23Ab.
我们评估了成纤维细胞生长因子 23(FGF23)在镰状细胞病(SCD)小鼠尿磷排泄中的作用。对照和 SCD 小鼠用 FGF23 中和抗体(FGF23Ab)处理 24 小时。SCD 小鼠的血清铁蛋白显著升高,FGF23Ab 可使雌性而非雄性 SCD 小鼠的血清铁蛋白显著降低。FGF23Ab 可显著降低 SCD 肾脏中红细胞生成素的增加。SCD 雌性小鼠的血清完整 FGF23 显著增加,SCD 雄性小鼠的血清完整 FGF23 显著增加;然而,FGF23Ab 可显著降低两种基因型和性别中的血清完整 FGF23。SCD IgG 雄性小鼠的血清羧基末端片段 FGF23(cFGF23)显著降低,SCD IgG 雌性小鼠的血清 cFGF23 显著降低,但不显著。FGF23Ab 可显著增加两种性别和基因型的 cFGF23。SCD IgG 中 1,25-二羟维生素 D3 血清显著增加,FGF23Ab 可进一步显著增加两种性别和基因型的 1,25-二羟维生素 D3 血清。SCD 中显著增加的血尿素氮不受 FGF23Ab 影响。SCD 中两性的尿磷(Pi)/肌酐比值均显著增加,FGF23Ab 可显著降低该比值。短期 FGF23Ab 可挽救 SCD 肾脏损伤标志物肾损伤分子 1 的增加,但不能挽救硬化肾小球、增加的巨噬细胞和淋巴细胞。FGF23Ab 可显著降低 SCD 肾脏中磷酸化成纤维细胞生长因子受体 1、αKlotho、磷酸化细胞外信号调节激酶、磷酸化血清/糖皮质激素调节激酶 1、磷酸化钠-氢交换调节因子-1、磷酸化 Janus 激酶 3 和磷酸化转录激活因子 3 的增加。SCD 肾脏中的 II 型钠磷共转运蛋白(NPT2a)和钠依赖性磷转运蛋白 PiT-2 蛋白显著降低,FGF23Ab 可增加这些蛋白。我们的结论是,增加的 FGF23/FGF 受体 1/αKlotho 信号通过调节多条信号通路,下调 NPT2a 和 PIT2,促进 SCD 中的 Pi 丢失,这些信号通路可通过 FGF23Ab 得到挽救。